In our cohort, LMWH-treated factor V Leiden carriers exhibited significant reductions in fetal growth restriction (FGR), gestational hypertension (GH), preeclampsia (PE), and recurrent pregnancy loss (RPL), supporting its role in improving placental perfusion and mitigating thrombotic complications. The gene discussed is F5; the disease is preeclampsia.